Skip to main content
. 2020 Jul 14;6(2):e001282. doi: 10.1136/rmdopen-2020-001282

Table 5.

Association between autoimmune thyroid disease and response to methotrexate at 3-month follow-up visit among 6025 RA -patients (3 395 non/moderate responders, 2 630 good responders) in the Swedish Rheumatology Quality Register (SRQ), imputed dataset

AITD in non/moderate responders (n)*(cases) AITD in good responders (n)* (controls) OR (95% CI)† OR (95% CI)‡
Overall 376 (11) 286 (11) 0.95 (0.80–1.13) 0.93 (0.78–1.10)
Sex
 Women 336 (14) 248 (15) 0.93 (0.78–1.12) 0.90 (0.75–1.08)
 Men 40 (4) 38 (4) 1.05 (0.66–1.69) 1.03 (0.64–1.66)
Age group
 <45 years 30 (9) 17 (6) 1.44 (0.76–2.76) 1.43 (0.74–2.75)
 ≥45 years 346 (11) 269 (11) 0.92 (0.77–1.10) 0.89 (0.75–1.07)
Serostatus
 RF and/or ACPA positive 265 (11) 192 (11) 0.99 (0.81–1.22) 0.95 (0.78–1.17)
 RF and ACPA negative 97 (10) 81 (10) 0.86 (0.62–1.20) 0.85 (0.60–1.18)
 Serostatatus unspecified 14 (20) 13 (16) 1.19 (0.50–2.84) 1.49 (0.59–3.72)

*According to EULAR response criteria including imputed values on response status. Values are the numbers (%).

†Adjusted for age and sex.

‡Adjusted for age, sex, cortisone, HAQ, smoking. Multiple imputations=50.

AITD, autoimmune thyroid disease; HAQ, Health Assessment Questionnaire Disability Index; RA, rheumatoid arthritis.